Skip to main content
. 2023 Jun 28;93:104682. doi: 10.1016/j.ebiom.2023.104682

Fig. 2.

Fig. 2

Pan-enteroviral inhibition by AAV2-CasRx-EV71_3Dguides. a. Assessment of inhibitory activity of the six-gRNAs pool targeting HFM41 strain on three other EV71 variants (H strain, B5 strain, and C4 strain). 10K RD cells were transduced with AAV2-CasRx at MOI of 10K, 100K, and 1000K bearing either GFP guide2 or EV-A71 guide(s) for 72 h and then subjected to EV-A71 infection at MOI of 1 for 12 h, after which the supernatant is harvested for virus plaque assay. b. The pool of 6 gRNAs designed against the HFM41 strain exhibits antiviral inhibition against three other EV71 variants (H strain, B5 strain, and C4 strain) at an MOI of 1000K. c. Each pool of 6 gRNAs is engineered specifically for the sequences of the H, B5, or C4 strain. d. Each re-engineered pool of 6 gRNAs exhibits antiviral inhibition against their respective H, B5, or C4 strain. In all panels, comparison between two groups (CasRx-GFPg2 and CasRx-EV71_3Dguides) was analyzed by Student t-test (two-tailed). ∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.001.